Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise
07:13am, Wednesday, 23'rd Jul 2025
A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several high-profile
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill.
04:00am, Wednesday, 23'rd Jul 2025
What makes a good dividend stock? The answer depends a bit on who's looking, of course.
Johnson & Johnson Stock Could Be Waking Up
03:11pm, Tuesday, 22'nd Jul 2025
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
12:56pm, Tuesday, 22'nd Jul 2025
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
10:01am, Tuesday, 22'nd Jul 2025
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Best Dividend Kings: July 2025
09:31am, Tuesday, 22'nd Jul 2025
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a
Build Stability and Income With 3 Overlooked Dividend Leaders
04:03pm, Monday, 21'st Jul 2025
Dividend investing is one of the most popular strategies among retail investors seeking a combination of stability and passive income. A long-term buy-and-hold approach for stalwart dividend players l
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
12:46pm, Monday, 21'st Jul 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Insider report: These stocks had the biggest sales by executives in the past week
10:50am, Monday, 21'st Jul 2025
Some investors follow company insiders on the notion that they would know better than anyone when it's the right time to buy or sell shares. CNBC rounded up some of the biggest sales over the last wee
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
10:46am, Monday, 21'st Jul 2025
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
10:41am, Monday, 21'st Jul 2025
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four P
3 High-Conviction Picks I Just Bought More Of For The Dividend Income Accelerator Portfolio
06:00pm, Sunday, 20'th Jul 2025
I added additional shares of Alphabet, PepsiCo, and the Schwab U.S. Dividend Equity ETF to The Dividend Income Accelerator Portfolio to optimize our portfolio's risk-reward, income, and growth balance
10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever
05:01am, Sunday, 20'th Jul 2025
Dividend stocks are one of the most powerful wealth compounders. The S&P 500 (SNPINDEX: ^GSPC) index offers the perfect example.
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
12:10pm, Friday, 18'th Jul 2025
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
